Point mutation of C-terminal region of CD20 molecule predicts rituximab-induced complement-dependent cytotoxicity and clinical response to rituximab in non-Hodgkin's lymphoma.

被引：0
|
作者：
Terui, Y.
Mishima, Y.
Mishima, Y.
Yokoyama, M.
Hatake, K.
Sugimura, N.
Kojima, K.
Sakurai, T.
Takeuchi, K.
机构：
[1] CIH, Tokyo, Japan
[2] Morinaga Milk Co, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：437S / 437S
页数：1
相关论文
共 47 条
  • [1] Use of C-terminal deletion mutation of CD20 molecule to predict CD20 expression and time to progression after rituximab in non-Hodgkin lymphoma
    Terui, Y.
    Mishima, Y.
    Yokoyama, M.
    Mishima, Y.
    Takeuchi, K.
    Ito, Y.
    Takahashi, S.
    Hatake, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Rituximab-induced antibody-dependent cellular cytotoxicity (ADCC) in follicular non-Hodgkin's lymphoma.
    Weng, WK
    Levy, R
    BLOOD, 2002, 100 (11) : 157A - 157A
  • [3] C-terminal deletion mutation of CD20 is related to low CD20 expression and shortened time to progression after rituximab treatment in non-Hodgkin's lymphoma
    Terui, Yasuhito
    Mishima, Yuji
    Hatake, Kiyohiko
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3396S - 3396S
  • [4] Lack of lipid raft domain reorganization following ligation of CD20 is associated with resistance to rituximab-induced complement-dependent cytotoxicity
    Olejniczak, SH
    Hernandez-Ilizaliturri, FJ
    Clements, JL
    Czuczman, MS
    BLOOD, 2005, 106 (11) : 284B - 284B
  • [5] Rituximab in the management of non-Hodgkin lymphoma. expressing CD20 (Egyptian single institution experience)
    Azim, HA
    Azim, HA
    Moneim, DA
    Kamal, NS
    ANNALS OF ONCOLOGY, 2005, 16 : 303 - 303
  • [6] Identification of CD20 mutation associated with modification of CD20 expression and poor prognosis after rituximab in non-Hodgkin's lymphoma
    Terui, Y.
    Mishima, Y.
    Yokoyama, M.
    Kodaira, M.
    Takeuchi, K.
    Hatake, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 115 - 115
  • [7] Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation
    Hayashi, Kazumi
    Nagasaki, Eijiro
    Kan, Shin
    Ito, Masaki
    Kamata, Yuko
    Homma, Sadamu
    Aiba, Keisuke
    CANCER SCIENCE, 2016, 107 (05): : 682 - 689
  • [8] Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma
    Terui, Yasuhito
    Mishima, Yuji
    Sugimura, Natsuhiko
    Kojima, Kiyotsugu
    Sakurai, Takuma
    Mishima, Yuko
    Kuniyoshi, Ryoko
    Taniyama, Akiko
    Yokoyama, Masahiro
    Sakajiri, Sakura
    Takeuchi, Kengo
    Watanabe, Chie
    Takahashi, Shunji
    Ito, Yoshinori
    Hatake, Kiyohiko
    CLINICAL CANCER RESEARCH, 2009, 15 (07) : 2523 - 2530
  • [9] CD20 mutation is associated with resistance to rituximab in a subset of patients with B-cell non-Hodgkin lymphoma
    Libra, Massimo
    Terzo, Maria N.
    Militello, Loredana
    Russo, Alessia E.
    Ligresti, Giovanni
    Russo, Mario
    Nicoletti, Ferdinando
    Stivala, Franca
    Bonavida, Benjamin
    Travali, Salvatore
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2010, 26 : S66 - S66
  • [10] Rituximab-induced Annexin-V staining of tumor cells does not predict clinical outcome following Rituximab treatment in follicular non-Hodgkin's lymphoma.
    Weng, WK
    Levy, R
    BLOOD, 2001, 98 (11) : 338A - 338A
12345